MIMEDX集团发布其活动试验的中期结果，表明其EPIEEETION在治疗不愈合糖尿病足溃疡方面显着优于标准护理

MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced the publication of interim results from its CAMPAIGN trial, a randomized controlled trial ("RCT") designed to evaluate the performance of the Company's EPIEFFECT® product in comparison to standard of care ("SOC") wound treatment.

The study, entitled "Evaluation of lyophilized human amnion/chorion membrane ("LHACM") in the management of nonhealing diabetic foot ulcers: an interim analysis of the CAMPAIGN trial," was recently published in the International Journal of Tissue Repair. Enrollment for CAMPAIGN is still ongoing; however, advanced predictive models indicate superiority of MIMEDX's EPIEFFECT over SOC based upon 71 enrolled patients. The Company also presented at the Tissue Research Evidence Summit ("TRES") in New Orleans, La. on October 30, 2025 with an expanded 88 patient sample set, further widening the gap between EPIEFFECT and SOC.

In the CAMPAIGN study design, success was defined as a posterior probability > 90%, and the interim results demonstrated the posterior probability that LHACM was superior to standard of care was 98.5%.

"Since its launch in 2023, EPIEFFECT has garnered significant praise for its clinical efficacy and utility. Until now, this has been based solely upon real-world evidence. We are, therefore, extremely pleased with the favorable results being demonstrated in this latest RCT. Thus far, EPIEFFECT recipients outperformed those treated with SOC, and we are optimistic that this study will have a successful read out upon completion," stated Joseph H. Capper, MIMEDX Chief Executive Officer.